| Product Name | NebuSelect™ Recombinant Mouse CD164, hFc-tag |
|---|---|
| Catalog Number | NBL-242890 |
| Alias/Synonyms | CD164; MUC-24; Endolyn; MGC-24; Cd164; CD164; MGC-24v; sialomucin |
| Appearance | see COA |
| Molecule Weight | Gln24-Asp162 |
| CAS | N/A |
| Solubility | Water Soluble |
| Storage | Short term 4℃; Long term -20℃. |
| Shelf Life | 2 years |
| Additional info 1 | Q9R0L9 |
| Additional info 2 |
| Catalog Numbe | Size | Price | Inventory Level | |
| NBL-242890-100ug | 100ug | Inquire | Inquire | |
| NBL-242890-1mg | 1mg | Inquire | Inquire | |
| NBL-242890-Customized Size | N/A | Inquire | Inquire |
Product Name:
NebuSelect™ Recombinant Mouse CD164, hFc-tag
Catalog#:
NBL-242890
Description:
NebuSelect™ Recombinant Mouse CD164, hFc-tag(Cat#NBL-242890) is expressed in HEK293 with hFc tag at the C-Terminus.It contains Gln24-Asp162.
Species:
Mouse
Expression System:
HEK293
Molecular Weight:
The protein has a predicted MW of 41.4 kDa. Due to glycosylation, the protein migrates to 70-115 kDa based on Bis-Tris PAGE result.
Target Name:
CD164; MUC-24; Endolyn; MGC-24; Cd164; CD164; MGC-24v; sialomucin
Target Information:
CD164 was found to play a role in many malignant diseases. CD164 was associated with clinical and pathological features of patients. High level of CD164 was related to the distant metastasis and vascular invasion of bladder cancer patients.CD164 was associated with the poor clinical outcomes of BC patients. Silencing of CD164 could inhibit the progression of tumors in vivo and in vitro, which may become an effective target in the treatment of bladder cancer.
Amino Acid Sequence:
Gln24-Asp162
Purity:
>95%
Formulation:
see COA
Endotoxin:
<1EU/ug(LAL Method)
Storage:
4°C for short term.
-20°C for long term.
To get more information, please contact us freely.